Xentech is a Contract Research Organization dedicated to cancer biomarkers and translational research in oncology which offers preclinical services to evaluate the anti-cancer potential of drug candidates. In addition, XenTech develops internal R&D programs to correlate drug response with molecular features of tumors and identify biomarkers and therapeutic targets.
Year of creation: 2006
Line of business: CRO
Institut Curie: Behind the technology and R&D partner
To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.